Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 552,023
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone: 1-800-474-2737
DriuxP
DriuxP Aug. 1 at 8:08 PM
$ATAI gorgeous performance out of ATAI today. $CMPS as well. $PSIL is a great move for those interested in this industry in general. Maybe some folks from $IBB would feel welcome here. Have a good weekend folks. Excited for next week!
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Aug. 1 at 6:25 PM
If you're not looking at biotech stocks today idk what you are looking at. $XBI $IBB $ONC $CNTA $ASND KNSA, MIRM, ALNY, SPRY, XERS
0 · Reply
BioRich
BioRich Aug. 1 at 5:37 PM
$ALT Legal Updates: 1) At least one class action lawsuit (CA-1) against $ALT has a Lead Plaintiff, and as such, will continue to move forward. 2) Another class action lawsuit is in the information gathering stages. They will likely have a lead plaintiff in the near future. 3) Both have the premise of Altimmune misleading shareholders and withholding material information. 4) Each will have slightly different areas of focus to maximize value for shareholders affected by $ALT's actions. 5) Class Period for CA-1 will include, "all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between March 27, 2024 and June 25, both dates inclusive". 6) CA-2 to include August 1, 2023, and June 25, 2025. 7) $ALT has at least 2 formal SEC complaints against them for misleading shareholders and/or withholding material information. This is not BS folks. This is real. Each is very well supported and VERY specific. $XBI $RUT $IBB $NDAQ
1 · Reply
framus_morrigan
framus_morrigan Aug. 1 at 2:11 PM
$SPY $QQQ $IWM $IBB Hello, I'm August
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Aug. 1 at 1:54 PM
$SRPT $IBB only down < 1% (good job)
0 · Reply
US_Bull
US_Bull Aug. 1 at 11:03 AM
$LLY $NVO $XBI $IBB Will pull up the sector today IMO.
0 · Reply
US_Bull
US_Bull Aug. 1 at 10:59 AM
$XBI $IBB $BCRX $NVCR Futures may look ugly because of tariff bs but bios and medico have been way oversold for years. I expect a green bio medico day today.
1 · Reply
Biotech_Beast
Biotech_Beast Jul. 31 at 8:26 PM
$EXEL has seen success in non-dMMR CRC with its drug zanzalintinib. There have been disappointments however, although the recent pull back has the name looking cheaper, and earnings are growing. $XBI $IBB https://seekingalpha.com/article/4806853-exelixis-zanzalintinib-sees-mixed-progress-cabozantinib-grinds-upwards
0 · Reply
Jcordless
Jcordless Jul. 30 at 8:21 PM
$ALT $IBB $QQQ $XBI it’s sad how much enjoyment you get out of this. Is spamming the ALT board your full time job or something? When do you plan to move on? Your behavior is narcissistic and your avatar is some random dude in a suit. You don’t have anything better to do than to poke at the community here?
4 · Reply
BioRich
BioRich Jul. 30 at 8:16 PM
$ALT Had this pointed out to me...Today is National Whistleblower Day. How ironic ALT Nation? $XBI $IBB $QQQ
0 · Reply
Latest News on IBB
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

Jul 6, 2025, 11:12 AM EDT - 27 days ago

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

XBI


Fast Money: WTI, IBB, UBER, CAT

Jun 13, 2025, 6:20 PM EDT - 7 weeks ago

Fast Money: WTI, IBB, UBER, CAT

UBER CAT


IBB: Now Is The Time To Be Contrarian

May 29, 2025, 10:59 AM EDT - 2 months ago

IBB: Now Is The Time To Be Contrarian


New vaccine chief rocks pharmaceutical stocks

May 7, 2025, 11:13 AM EDT - 3 months ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK SRPT XBI


Sell into strength in pharma, says Mizuho's Jared Holz

Apr 11, 2025, 7:17 PM EDT - 4 months ago

Sell into strength in pharma, says Mizuho's Jared Holz

XBI


Invest In A New Biotech Bull Market With XBI And IBB

Mar 2, 2025, 8:33 AM EST - 5 months ago

Invest In A New Biotech Bull Market With XBI And IBB

XBI


iShares Biotechnology ETF: Playing Defense

Dec 10, 2024, 1:33 PM EST - 8 months ago

iShares Biotechnology ETF: Playing Defense


Health care stocks jump on Trump's nominee for FDA head

Nov 25, 2024, 6:22 PM EST - 8 months ago

Health care stocks jump on Trump's nominee for FDA head

HIMS LFMD MRNA PFE


Final Trade: Euro, IBB, SMH, NEM

Nov 20, 2024, 6:21 PM EST - 9 months ago

Final Trade: Euro, IBB, SMH, NEM

SMH NEM


Analyst is 'extremely bullish' on biopharma

Jul 30, 2024, 3:25 PM EDT - 1 year ago

Analyst is 'extremely bullish' on biopharma

MRK PFE


Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

XBI


For Biotech Stocks To Move Higher, This Must Move Lower

May 13, 2024, 9:00 AM EDT - 1 year ago

For Biotech Stocks To Move Higher, This Must Move Lower

XBI


Biotech's Next Gold Rush: Weight-Loss Drugs

Apr 2, 2024, 4:56 PM EDT - 1 year ago

Biotech's Next Gold Rush: Weight-Loss Drugs

LLY NVO


Catch The Medical Breakthroughs With The IBB ETF

Mar 28, 2024, 2:01 AM EDT - 1 year ago

Catch The Medical Breakthroughs With The IBB ETF


IBB: Let It Rest

Mar 26, 2024, 4:46 AM EDT - 1 year ago

IBB: Let It Rest


Why Biotech Stocks May Be Ready For A Recovery

Mar 9, 2024, 3:59 AM EST - 1 year ago

Why Biotech Stocks May Be Ready For A Recovery

BBH XLV


Navigating the big run in biotech

Feb 15, 2024, 1:44 PM EST - 1 year ago

Navigating the big run in biotech

XBI


Healthcare In 2024: Navigating The Biopharma Bull Run

Jan 17, 2024, 11:22 PM EST - 1 year ago

Healthcare In 2024: Navigating The Biopharma Bull Run

FHLC IYH PPH VHT XBI XLV


Equity CEFs/ETFs: Top Picks For 2024 - Part II

Jan 5, 2024, 11:01 AM EST - 1 year ago

Equity CEFs/ETFs: Top Picks For 2024 - Part II

AIO AIQ BIB DIG EOI ETW EXG


Dr. Scott Gottlieb talks Big Pharma's buying spree

Dec 27, 2023, 4:26 PM EST - 1 year ago

Dr. Scott Gottlieb talks Big Pharma's buying spree

XBI


DriuxP
DriuxP Aug. 1 at 8:08 PM
$ATAI gorgeous performance out of ATAI today. $CMPS as well. $PSIL is a great move for those interested in this industry in general. Maybe some folks from $IBB would feel welcome here. Have a good weekend folks. Excited for next week!
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Aug. 1 at 6:25 PM
If you're not looking at biotech stocks today idk what you are looking at. $XBI $IBB $ONC $CNTA $ASND KNSA, MIRM, ALNY, SPRY, XERS
0 · Reply
BioRich
BioRich Aug. 1 at 5:37 PM
$ALT Legal Updates: 1) At least one class action lawsuit (CA-1) against $ALT has a Lead Plaintiff, and as such, will continue to move forward. 2) Another class action lawsuit is in the information gathering stages. They will likely have a lead plaintiff in the near future. 3) Both have the premise of Altimmune misleading shareholders and withholding material information. 4) Each will have slightly different areas of focus to maximize value for shareholders affected by $ALT's actions. 5) Class Period for CA-1 will include, "all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between March 27, 2024 and June 25, both dates inclusive". 6) CA-2 to include August 1, 2023, and June 25, 2025. 7) $ALT has at least 2 formal SEC complaints against them for misleading shareholders and/or withholding material information. This is not BS folks. This is real. Each is very well supported and VERY specific. $XBI $RUT $IBB $NDAQ
1 · Reply
framus_morrigan
framus_morrigan Aug. 1 at 2:11 PM
$SPY $QQQ $IWM $IBB Hello, I'm August
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Aug. 1 at 1:54 PM
$SRPT $IBB only down < 1% (good job)
0 · Reply
US_Bull
US_Bull Aug. 1 at 11:03 AM
$LLY $NVO $XBI $IBB Will pull up the sector today IMO.
0 · Reply
US_Bull
US_Bull Aug. 1 at 10:59 AM
$XBI $IBB $BCRX $NVCR Futures may look ugly because of tariff bs but bios and medico have been way oversold for years. I expect a green bio medico day today.
1 · Reply
Biotech_Beast
Biotech_Beast Jul. 31 at 8:26 PM
$EXEL has seen success in non-dMMR CRC with its drug zanzalintinib. There have been disappointments however, although the recent pull back has the name looking cheaper, and earnings are growing. $XBI $IBB https://seekingalpha.com/article/4806853-exelixis-zanzalintinib-sees-mixed-progress-cabozantinib-grinds-upwards
0 · Reply
Jcordless
Jcordless Jul. 30 at 8:21 PM
$ALT $IBB $QQQ $XBI it’s sad how much enjoyment you get out of this. Is spamming the ALT board your full time job or something? When do you plan to move on? Your behavior is narcissistic and your avatar is some random dude in a suit. You don’t have anything better to do than to poke at the community here?
4 · Reply
BioRich
BioRich Jul. 30 at 8:16 PM
$ALT Had this pointed out to me...Today is National Whistleblower Day. How ironic ALT Nation? $XBI $IBB $QQQ
0 · Reply
Gnugnu
Gnugnu Jul. 30 at 7:06 PM
$XBI $IBB $LABU looks like the big pattern on the daily chart was a fakeout. It's a common thing in this sector. Price target for Xbi is 40$
0 · Reply
BioAmerica
BioAmerica Jul. 30 at 11:51 AM
$XBI $IBB Just listened to the FDA commissioner in an interview on CNBC. This guy makes a lot of sense. He is troubled with time involved to get drugs approved. He talked about all the "down time" involved in the process. He is questioning why applications have be submitted all at once, while some things, like the manufacturing process, cannot be approved while trials are still on-going. He said he wants to get the final approval time down to a month, from nearly a year under the current process. If he can get even half of what he wants to do through, and the rules changed, we may see a new age in biotech. Good things are coming. If you get a chance to replay the interview, do so. I think anyone who invests in biotech will be jumping for joy that we finally might have someone who wants to change this system.
0 · Reply
free2dream
free2dream Jul. 30 at 10:46 AM
$SRPT $200 stock trading at $15 is pathetic ! Destruction of the XBI and $IBB sector by unqualified RFK AND PRASAD is absolutely ridiculous. American biotech innovation won't stop just because of these two clowns. They will be bother removed eventually !
0 · Reply
NewbieInvester
NewbieInvester Jul. 30 at 7:07 AM
$XBI $IBB $LABU give me a pure play on a designer baby human gene editing stock, even to correct for rare non-life threatening defects initially. Then, I will get bullish here.
0 · Reply
BluntForceOptions
BluntForceOptions Jul. 30 at 5:01 AM
$SRPT $SLDB $XBI $IBB $IWM Prasad's FDA stint lasted shorter than a microcap pump.
2 · Reply
Honeystocks
Honeystocks Jul. 29 at 4:05 PM
The world is waking up. After the covid poison shots at $MRNA and $PFE, the market is now forward looking the outcomes from the poison weight loss shots of $NVO. Moderna lost 95% of it's value in just a few years. When will people realise they don't need big pharma for general health and wellbeing? $XBI $IBB
5 · Reply
free2dream
free2dream Jul. 29 at 1:48 PM
$XBI let the $SMH blow their brains out, the $XBI and $IBB will catch up at some point !
1 · Reply
Shanthi_Rexaline
Shanthi_Rexaline Jul. 29 at 9:28 AM
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers https://stocktwits.com/news-articles/markets/equity/astrazeneca-q2-beats-on-cancer-drug-sales-maintains-guidance-shares-rise-premarket/cho9ppoR5U0 $AZN $IBB $IBBQ
0 · Reply
biotech
biotech Jul. 28 at 8:55 AM
$XBI $IBB $NBI Houston, We Have Inflows!
0 · Reply
usiv
usiv Jul. 28 at 12:19 AM
$XBI expecting it break that 200sma and close above 90 this week as $IBB already done that last week
0 · Reply
muldoon92
muldoon92 Jul. 27 at 10:17 PM
$VRTX has reclaimed the 200-day MA twice now recently, included a pretty little backtest with a hammer close Friday. I don't think we are going below that again unless brought on by a news triggered event (aka earnings on 8/4). Much much more likely to press into gap fill to 500 territory imminently: 489.1 yearly pivot line (blue dashed line) first, then 498.45 quarterly pivot (grey dashed line) next. IF we push into that area before earnings, I will likely offload some shares and sell the replacement equivalent in puts following the decent sized October 420 put sale I caught across the tape Friday. Would happily take re-assignment there if it were to come. A lot of post-ER movement is going to come down to Journavx commentary/guidance IMO even though actual revenue is nominal at this point. $IBB $XBI $LABU
0 · Reply
Wallst45
Wallst45 Jul. 27 at 10:07 PM
$XBI $IBB $PFE $BMY $ABBV Pharma only at 15%, this is Huge news
1 · Reply